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Summary
anticollapsin-responsive mediator protein 5 (CrMp-5) 
IgG is an antibody generally associated with small-cell 
lung cancer, which is known to cause paraneoplastic 
neurological syndromes, including encephalitis, myelitis 
and neuropathy. HIV escape is a phenomenon in which 
a patient with low or undetectable levels of HIV rNa in 
plasma is found to have elevated levels in cerebrospinal 
fluid (CsF). We present a case of a 58-year-old HIV-
positive woman with undetectable plasma viral load 
who developed a subacute flaccid paraparesis. over the 
course of 4 months, she had a broad inflammatory and 
infectious workup that was unrevealing until repeat 
imaging showed an inflammatory myelitis. Workup was 
notable for elevated HIV rNa copies in CsF, as well as 
anti-CrMp-5 autoantibodies in serum. Despite changing 
her antiretroviral therapy and multiple modalities of 
immunomodulation, the patient failed to respond 
adequately to treatment. this case illustrates a complex 
clinical picture with a unique presentation of anti-
CrMp-5 myelitis.
BaCkground
Collapsin-responsive mediator protein 5 (CRMP-5) 
is a synaptic protein that is implicated in parane-
oplastic syndromes associated with small-cell lung 
carcinoma (77% of cases) and thymoma (6%).1 Its 
presentation can include a variety of neurological 
disorders, including encephalopathy, myelopathy, 
radiculopathy, optic neuropathy and chorea.1 This 
is the first report of CRMP-5-mediated myelitis in 
the context of HIV infection.
Early in HIV infection, cerebrospinal fluid (CSF) 
infection is equilibrated with plasma infection, 
but localised amplification can result in compart-
mentalisation of populations of viruses in the 
CSF that differ from plasma populations. Over 
time, M-tropic R5 viruses that infect macrophages 
(unlike T-tropic viruses that infect T cells predom-
inantly early in disease) can evolve in CSF. These 
are suspected to be linked to the development of 
central nervous system (CNS) disease.2 As such, 
rarely, patients with HIV on antiretroviral therapy 
(ART) with suppressed plasma HIV viral loads can 
present with ‘CNS escape’, in which the CNS infec-
tion may no longer be susceptible to their ART as 
a result of a different population developing in the 
CNS.2 3 Symptomatic CNS escape is associated with 
CSF pleiocytosis.3
Manifestations of HIV in the spinal cord 
include vacuolar myelopathy and HIV myelitis, 
and distinction between these two entities is vital. 
While vacuolar myelopathy is a non-inflammatory 
vacuolation predominantly of the lateral and poste-
rior white matter by lipid-laden macrophages, HIV 
myelitis is a more acute and very rare inflammatory 
condition associated with CSF pleiocytosis, which 
is considered to be directly attributable to HIV 
infection, although poorly understood.4 5
We describe a patient with a clinical course that 
was more subacute than is typical for a primary 
inflammatory HIV myelitis. Further testing revealed 
both CNS HIV escape and, later, anti-CRMP-5 
IgG antibodies in CSF. Suspicion of inflammatory 
myelitis due to HIV led to a delay in diagnosis 
and definitive treatment of the antibody-mediated 
disorder, with attendant poor clinical outcome.
CaSe preSenTaTion
A 58-year-old African–American woman with 
a history of well-controlled HIV and history of 
breast cancer and hepatitis C presented to the 
emergency department with papilledema. Neuro-
imaging was normal and CSF analysis showed 
pleiocytosis but no other abnormalities. Two 
months prior to the development of papill-
edema, she underwent a change in her ART (from 
cobicistat–elvitegravir–emtricitabine–tenofovir 
alafenamide+atazanavir to darunavir–cobici-
stat+emtricitabine tenofovir alafenamide) due to 
adverse effects.
The patient re-presented within a month with 
subacute back pain and began developing progres-
sive bilateral lower extremity weakness to the point 
that she stopped ambulating. She had no sensory 
changes aside from pain in the upper back and 
in the lower back and legs. She had begun to use 
a diaper due to impaired mobility but retained 
control of urination and bowel movements. This 
prompted several hospital admissions for failure 
to thrive, despite repeated serial MRI studies with 
gadolinium of the brain and spine revealing no 
acute abnormalities. Figure 1 summarises the time-
line of clinical events.
Four months following her initial symptoms, the 
patient presented again to the emergency depart-
ment; examination was notable for no observed 
movement at rest in the bilateral lower extrem-
ities. With encouragement, she provided a flicker 
of unsustained movement in the hip flexors, abduc-
tors, adductors and great toe flexion. She was inter-
mittently tearful but alert, oriented in detail and 
conversant. Cranial nerve testing did not reveal any 
deficits, and there was no papilledema at this time. 
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Sensory examination was equal and symmetric in all modalities. 
Reflexes were normal, equal and symmetric, though her toes 
were noted to be intermittently upgoing. Coordination was 
intact in the upper extremities. She was not able to walk.
This examination was clearly different from an examination 
with neurology 1 month previously, where she was noted to have 
4+/5 strength throughout the lower extremities (limited due to 
effort and pain) without other objective findings.
During the course of her illness, she had a total of three 
lumbar punctures, all of which demonstrated CSF pleiocytosis 
(88%–98% lymphocytes) but were otherwise unremarkable in 
more specific infectious and neoplastic studies. Her workup also 
included broad-serum studies, notable for an elevated antinu-
clear antibody level.
inveSTigaTionS
Despite previous spinal MRIs being unrevealing, an MRI spine 
survey without and with contrast was repeated and now demon-
strated diffuse longitudinal cord oedema and patchy enhancement, 
greatest along the lateral spinal tracts, from the cervicomedullary 
junction to the distal cord at L1 (figure 2). Additionally, mild 
compression of the ventral cord at C3–C4 due to spinal stenosis 
was noted and unchanged from previous imaging.
Further workup revealed a CD4 level of 379 with HIV-1 RNA 
undetectable in serum. Antinuclear antibodies were significantly 
elevated with a titre of >1:640 in a speckled pattern.
Analysis of the CSF included total red blood cells of 360, 
total white blood cells of 86 (12% macrophages and 86% 
lymphocytes (65% small T cells and 18% small mature B cells)), 
protein level of 353 mg/dL, glucose level of 101 mg/dL and 
lactate concentration of 4.3 mmol/L. Opening pressure was not 
obtained due to positioning in a technically difficult procedure. 
CSF HIV RNA quantitative PCR was elevated at 1110 copies/
mL and 3.05 log copies/mL.
Anti-CRMP-5 IgG antibody, as part of a serum paraneoplastic 
encephalomyelitis panel, returned positive several weeks after 
the above testing, with no other autoantibodies detected. CT of 
the chest, abdomen and pelvis with contrast were negative for 
evidence of malignancy.
Other negative or unrevealing serological studies included 
creatine phosphokinase, anti-ribonucleoprotein, anti-double-
stranded DNA, anti-Smith, anti-Jo, anti-aquaporin-4, C3, C4, 
aldolase, ACE and Bartonella henselae IgG/IgM, Brucella anti-
body, human T-lymphotrophic (HTLV) I/II antibody, mumps 
IgG/IgM and measles IgG/IgM. Negative CSF studies included 
ACE, veneral disease research laboratory (VDRL) test, Esch-
erichia coli K1 PCR, Haemophilus influenzae PCR, Listeria 
monocytogenes PCR, Neisseria meningitides PCR, Streptococcus 
agalactiae PCR, S. pneuomoniae PCR, cytomegalovirus PCR, 
enterovirus PCR, herpes simplex virus 1 and 2 PCR, human-
herpes virus 6 PCR, varicella zoster virus PCR, John Cunningham 
virus (JCV) PCR, parechovirus PCR, Cryptococcus neoformans 
PCR, West Nile virus IgG/IgM, California encephalitis IgG/IgM, 
St. Louis encephalitis IgG/IgM, Eastern equine encephalitis IgG/
IgM, Western equine encephalitis IgG/IgM, HTLV I/II ELISA, 
cytology and flow cytometry (prior to receiving steroids).
differenTial diagnoSiS
Among the initial concerns included neuromyelitis optica spec-
trum disorder or other demyelinating disease; infectious processes; 
malignancy, such as lymphoma or glioma; or other inflammatory 
conditions, such as sarcoidosis. When the patient's CSF HIV viral 
load returned elevated without evidence of other infections, a 
preliminary diagnosis of HIV-related inflammatory myelopathy 
with escape was suggested; however, this was considered less likely 
after her anti-CRMP-5 antibody returned elevated.
TreaTmenT
When her CSF HIV RNA returned elevated, dolutegravir was 
added due to concern for resistant HIV within the CNS. CSF HIV 
RNA remained detectable at 180 copies/mL, and 2 months later, 
etravirine was added to specifically target M-tropic R5 HIV.
After her MRI showed new spinal cord oedema, the patient 
was started empirically on 1000 mg methylprednisolone daily 
for 3 days followed by a slow taper of oral steroids. Her pain 
improved without appreciable change in her neurological exam. 
Her anti-CRMP-5 IgG returned later, at which point she was 
treated with two courses of plasma exchange. Despite this, her 
symptoms progressed, and she developed weakness in the arms 
figure 1 Timeline of the patient’s pertinent clinical events and diagnostic results. BUE, bilateral upper extremities; CNS, central nervous system; 
CRMP-5, collapsin-responsive mediator protein 5; CSF, cerebrospinal fluid; IVIG, intravenous immunoglobulin; LP, lumbar punctures.
figure 2 Sagittal T2-weighted MRI image without contrast 
demonstrating cord oedema (open arrows) in the cervical (A) and 
thoracic (B) spinal cord. An axial image (C) in the thoracic cord 
demonstrates the involvement of the lateral tracts.
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and respiratory weakness. She was treated with intravenous 
immunoglobulin and, ultimately, rituximab without clinical 
improvement. Most recently, she was started on mycophenolate 
mofetil.
ouTCome and follow-up
At the time of diagnosis, our patient had endured approximately 
4 months of back pain and mild leg weakness, progressing to 
flaccid paraplegia. She had radiographic improvement tran-
siently in response to steroids but soon developed weakness in 
the arms, despite escalating doses. At her most recent follow-up 
appointment (approximately 10 months after her diagnosis), she 
remains quadriparetic and fully dependent on caregivers for all 
activities of daily living.
diSCuSSion
A review of the published literature revealed no reported cases 
of CRMP-5 antibody-mediated neurological disease in HIV. 
Given the presence of CRMP-5 antibodies in CSF with chronic 
progressive flaccid myelitis and presumed optic neuritis followed 
by no response to antiretroviral intensification for CSF escape, 
we believe the CRMP-5 antibodies are responsible for her clin-
ical disease. However, a causal relationship cannot be defini-
tively confirmed. The most likely explanation for CSF escape 
is that the inflammatory response to the CRMP-5 autoantibody 
amplified HIV replication in the CNS, as has been seen in other 
disorders causing pleiocytosis.6 In a patient with no known 
malignancy, it is not clear why she was at risk of CRMP-5-asso-
ciated myelitis and whether her HIV predisposed her to this, as 
there have been no previous cases reported of a CRMP-5-medi-
ated neurological syndrome in the setting of HIV.
Despite aggressive immunotherapy, our patient failed to make 
a significant clinical improvement. CRMP-5-associated neuro-
logical disorders, in general, are poorly responsive to treatment.1 
It also remains possible that despite an extensive radiographic 
search for underlying malignancy, she may have a neoplasm that 
is thus far too small to detect and continues to stimulate anti-
CRMP-5 antibody production.
This is the first documented case of CRMP-5-associated 
myelitis masquerading as an HIV escape phenomenon to our 
knowledge. It illustrates the need for exhaustive testing to arrive 
at a final diagnosis to best guide treatment and prognosis.
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learning points
 ► Cerebrospinal fluid HIV escape describes the finding of 
elevated HIV RNA with low or undetectable titres in the 
serum.
 ► HIV escape may or may not be associated with HIV-related 
central nervous system disease, and further testing may be 
necessary to reach a final diagnosis.
 ► CRMP-5 antibodies generally are associated with neoplasms 
but should be considered in patients with HIV who present 
with inflammatory myelitis.
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